GNPX News and Press, Genprex Inc. From 06/08/20

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will present at the MoneyShow June Virtual Event at 12:50 p.m. EDT on Wednesday, June 10, 2020. According to the upda...

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that the Company will present at the MoneyShow June Virtual Even...

Genprex (NASDAQ: GNPX) today announced the exercise of warrants to purchase approximately 5.4 million shares of common stock issued in connection with capital raises in May 2018 and November 2019 with two institutional investors at a price of $0.46 per share, resulting in its receipt of appr...

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced today that warrants to purchase approximately 5.4 million shares ...

Gainers: Portola Pharmaceuticals (NASDAQ: PTLA ) +130% . More news on: Portola Pharmaceuticals, Inc., CleanSpark, Inc., Genprex, Inc., Stocks on the move, , Read more ...

Portola Pharmaceuticals (NASDAQ: PTLA ) +131%  on being acquired for $18/share. More news on: Portola Pharmaceuticals, Inc., SG Blocks, Inc., MicroVision, Inc., Stocks on the move, , Read more ...

May 5, 2020 Palm Beach, FL – May 5, 2020 – The global market for cancer therapies is projected to reach US$220. 5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the diseas...

Nano cap Genprex (NASDAQ: GNPX ) jumps  39%  premarket on robust volume in reaction to its agreement with MD Anderson Cancer Center for exclusive global rights to a portfolio of 16 patent applications and related technology for the treatment of cancer using TUSC2 gene therapy Onc...

New license agreement expands Genprex’s oncology franchise Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs, including: Pembrolizumab (Merck’s largest selling drug Keytruda®) Nivolumab (Bristol-Myer...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights the Company’s progres...